36
Participants
Start Date
May 26, 2020
Primary Completion Date
November 11, 2020
Study Completion Date
January 20, 2021
HST 001
Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of active treatment (HST 001).
Phosphate Buffered Saline
Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of placebo control (Phosphate Buffered Saline).
California Dermatology & Clinical Research Institute, Encinitas
Lead Sponsor
Histogen
INDUSTRY